Alamar Biosciences Launches First Blood-Based eMTBR-Tau Assay for Alzheimer’s Research
Event summary
- Alamar Biosciences launched the first commercial eMTBR-Tau immunoassay on July 7, 2026.
- The assay is available in the NULISAseq™ Neuro 220 multiplexed panel kits and as a single-plex assay through TAP.
- eMTBR-Tau measures tau tangle pathology, a key biomarker for Alzheimer’s disease diagnosis and therapy monitoring.
- Alamar will present performance data at AAIC 2026 in London on July 14, 2026.
The big picture
Alamar’s eMTBR-Tau assay addresses a critical gap in Alzheimer’s diagnostics by providing a blood-based alternative to expensive tau PET imaging. This launch aligns with broader industry trends toward precision proteomics and non-invasive biomarker detection, potentially lowering barriers for clinical trials and therapeutic development.
What we're watching
- Diagnostic Adoption
- How quickly researchers and clinicians will integrate eMTBR-Tau into Alzheimer’s disease staging and therapy monitoring.
- Competitive Positioning
- Whether Alamar can maintain its lead in blood-based proteomics amid intense competition.
- Regulatory Pathway
- The pace at which the FDA or other regulators may require additional validation for clinical use.
Related topics